Stem cell engineering of striatal medium spiny neurons (MSNs) is a promising strategy to understand dis- eases affecting the striatum and for cell-replacement therapies in different neurological diseases. Protocols to generate cells from human pluripotent stem cells (PSCs) are scarce and how well they recapitulate the endogenous fetal cells remains poorly understood. We have developed a protocol that modulates cell seed- ing density and exposure to specific morphogens that generates authentic and functional D1- and D2-MSNs with a high degree of reproducibility in 25 days of differentiation. Single-cell RNA sequencing (scRNA-seq) shows that our cells can mimic the cell-fate acquisition steps observed in vivo in terms of cell type compo- sition, gene expression, and signaling pathways. Finally, by modulating the midkine pathway we show that we can increase the yield of MSNs. We expect that this protocol will help decode pathogenesis factors in striatal diseases and eventually facilitate cell-replacement therapies for Huntington’s disease (HD).

In vitro-derived medium spiny neurons recapitulate human striatal development and complexity at single-cell resolution / P. Conforti, V.D. Bocchi, I. Campus, L. Scaramuzza, M. Galimberti, T. Lischetti, F. Talpo, M. Pedrazzoli, A. Murgia, I. Ferrari, C. Cordiglieri, A. Fasciani, E. Arenas, D. Felsenfeld, G. Biella, D. Besusso, E. Cattaneo. - In: CELL REPORTS. METHODS. - ISSN 2667-2375. - 2:12(2022 Dec 19), pp. 100367.1-100367.18. [10.1016/j.crmeth.2022.100367]

In vitro-derived medium spiny neurons recapitulate human striatal development and complexity at single-cell resolution

P. Conforti
Primo
;
V.D. Bocchi;I. Campus;L. Scaramuzza;M. Galimberti;T. Lischetti;A. Murgia;I. Ferrari;G. Biella;D. Besusso
Penultimo
;
E. Cattaneo
Ultimo
2022

Abstract

Stem cell engineering of striatal medium spiny neurons (MSNs) is a promising strategy to understand dis- eases affecting the striatum and for cell-replacement therapies in different neurological diseases. Protocols to generate cells from human pluripotent stem cells (PSCs) are scarce and how well they recapitulate the endogenous fetal cells remains poorly understood. We have developed a protocol that modulates cell seed- ing density and exposure to specific morphogens that generates authentic and functional D1- and D2-MSNs with a high degree of reproducibility in 25 days of differentiation. Single-cell RNA sequencing (scRNA-seq) shows that our cells can mimic the cell-fate acquisition steps observed in vivo in terms of cell type compo- sition, gene expression, and signaling pathways. Finally, by modulating the midkine pathway we show that we can increase the yield of MSNs. We expect that this protocol will help decode pathogenesis factors in striatal diseases and eventually facilitate cell-replacement therapies for Huntington’s disease (HD).
Settore BIO/14 - Farmacologia
   European stem cell consortium for neural cell replacement, reprogramming and functional brain repair
   NEUROSTEMCELLREPAIR
   EUROPEAN COMMISSION
   FP7
   602278

   Novel Strategies for Cell-based Neural Reconstruction (NSC-Reconstruct)
   NSC-Reconstruct
   EUROPEAN COMMISSION
   H2020
   874758
19-dic-2022
https://www.sciencedirect.com/science/article/pii/S2667237522002697
Article (author)
File in questo prodotto:
File Dimensione Formato  
PIIS2667237522002697.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.52 MB
Formato Adobe PDF
5.52 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/949402
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 0
social impact